The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Lancet Oncol. 2014 Mar;15(3):e112-8. doi: 10.1016/S1470-2045(13)70578-3. Epub 2014 Feb 14.
Cancer costs continue to increase alarmingly despite much debate about how they can be reduced. The oncology community needs to take greater responsibility for our own practice patterns, especially when using expensive tests and treatments with marginal value: we cannot continue to accept novel therapeutics with very small benefits for exorbitant prices. Patients, payers, and pharmaceutical communities should be constructively engaged to communicate medically and economically possible goals, and eventually, to reduce use and costs. Diagnostic tests and treatments should have to show true value to be added to existing protocols. In this article, we discuss three key drivers of costs: end-of-life care patterns, medical imaging, and drugs. We propose health-care models that have the potential to decrease costs and discuss solutions to maintain clinical benefit at an affordable price.
尽管关于如何降低癌症成本存在很多争议，但癌症成本仍在惊人地持续上升。肿瘤学界需要对我们自己的治疗模式承担更多的责任，尤其是在使用昂贵但价值有限的检查和治疗方法时：我们不能继续接受那些价格昂贵但获益甚微的新型疗法。患者、支付方和制药界应积极参与，以沟通医疗和经济上可行的目标，并最终减少使用和成本。诊断性检查和治疗方法必须具有真正的价值，才能被添加到现有的治疗方案中。在本文中，我们讨论了成本的三个关键驱动因素：临终关怀模式、医学影像和药物。我们提出了具有降低成本潜力的医疗保健模式，并讨论了以可负担的价格维持临床获益的解决方案。
